Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: GlobeNewswire
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the first patients in Ireland were treated with ILUVIEN®, its sustained release intravitreal implant for the treatment of diabetic macular edema (DME). “The availability of ILUVIEN in Ireland is good news for patients and retina specialists alike,” said Mr. David Kent M.D., Consultant Ophthalmic Surgeon & Retinal Specialist of The Vision Clinic in Ireland. “ILUVIEN offers Irish patients struggling on other DME therapies the possibility of improved vision with fewer injections. Now that I have given my first two treatments, I look forward to offering ILUVIEN to other suitable patients.” “We are pleased that Mr. Kent and other surgeons in Ireland are now able to utilize the continuous microdosing of ILUVIEN for their DME patients,” said Dan Myers, Alimera’s CEO. “Ireland joins a g
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Luckie & Company Acquires Marbury Creative Group [Yahoo! Finance]Yahoo! Finance
- Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
ALIM
Earnings
- 3/7/24 - Miss
ALIM
Sec Filings
- 4/2/24 - Form 4
- 3/13/24 - Form 4
- 3/13/24 - Form 4
- ALIM's page on the SEC website